85
Views
4
CrossRef citations to date
0
Altmetric
Original Research

MiR-183-5p Promotes Tumor Progression of Osteosarcoma and Predicts Poor Prognosis in Patients

, , &
Pages 805-814 | Published online: 27 Jan 2021

References

  • Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017;13(8):480–491. doi:10.1038/nrendo.2017.1628338660
  • Morrow JJ, Khanna C. Osteosarcoma genetics and epigenetics: emerging biology and candidate therapies. Crit Rev Oncog. 2015;20(3–4):173–197. doi:10.1615/CritRevOncog.201501371326349415
  • Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ, Rao BN. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer. 1999;86(8):1602–1608. doi:10.1002/(SICI)1097-0142(19991015)86:8<1602::AID-CNCR31>3.0.CO;2-R10526292
  • Anderson ME. Update on survival in osteosarcoma. Orthop Clin North Am. 2016;47(1):283–292. doi:10.1016/j.ocl.2015.08.02226614941
  • Letson GD, Muro-Cacho CA. Genetic and molecular abnormalities in tumors of the bone and soft tissues. Cancer Control. 2001;8(3):239–251. doi:10.1177/10732748010080030411378650
  • Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15(5):429. doi:10.2174/13892010150514082816133525189575
  • Qadir MI, Faheem A. miRNA: a diagnostic and therapeutic tool for pancreatic cancer. Crit Rev Eukaryot Gene Expr. 2017;27(3):197–204. doi:10.1615/CritRevEukaryotGeneExpr.201701949429199604
  • Sun Z, Shi K, Yang S, et al. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17(1):147. doi:10.1186/s12943-018-0897-730309355
  • Wang J, Liu S, Shi J, et al. The role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma. Cancer Biother Radiopharm. 2019;34(10):605–613. doi:10.1089/cbr.2019.293931674804
  • Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH, Wang WJ. MicroRNAs in osteosarcoma. Clinica Chimica Acta. 2015;444:9–17. doi:10.1016/j.cca.2015.01.025
  • Li W, Cui X, Qi A, Yan L, Wang T, Li B. miR-183-5p acts as a potential prognostic biomarker in gastric cancer and regulates cell functions by modulating EEF2. Pathol Res Pract. 2019;215(11):152636. doi:10.1016/j.prp.2019.15263631558304
  • Waseem M, Ahmad MK, Serajuddin M, Bhaskar V, Sankhwar SN, Mahdi AA. MicroRNA-183-5p: a new potential marker for prostate cancer. Indian J Clin Biochem. 2019;34(2):207–212. doi:10.1007/s12291-017-0731-931092995
  • Li H, Pan X, Gui Y, et al. Upregulation of miR-183-5p predicts worse survival in patients with renal cell cancer after surgery. Cancer Biomarkers. 2019;24(2):153–158. doi:10.3233/CBM-18204730689558
  • Cheng Y, Xiang G, Meng Y, Dong R. MiRNA-183-5p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting the PDCD4. Reprod Biol. 2016;16(3):225–233. doi:10.1016/j.repbio.2016.07.00227476679
  • Meng F, Zhang L. miR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition. Exp Cell Res. 2019;374(2):315–322. doi:10.1016/j.yexcr.2018.12.00330528264
  • Zhang W, Zhang M, Liu L, Jin D, Wang P, Hu J. MicroRNA-183-5p inhibits aggressiveness of cervical cancer cells by targeting integrin subunit beta 1 (ITGB1). Med Sci Monit. 2018;24:7137–7145. doi:10.12659/MSM.91029530293085
  • Yan H, Sun BM, Zhang YY, et al. Upregulation of miR-183-5p is responsible for the promotion of apoptosis and inhibition of the epithelial-mesenchymal transition, proliferation, invasion and migration of human endometrial cancer cells by downregulating Ezrin. Int J Mol Med. 2018;42(5):2469–2480. doi:10.3892/ijmm.2018.385330226564
  • Zheng Z, Zheng X, Zhu Y, et al. miR-183-5p inhibits occurrence and progression of acute myeloid leukemia via targeting erbin. Mol Ther. 2019;27(3):542–558. doi:10.1016/j.ymthe.2019.01.01630799283
  • Zhu J, Feng Y, Ke Z, et al. Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 2012;180(6):2440–2451. doi:10.1016/j.ajpath.2012.02.02322525461
  • Yang X, Wang L, Wang Q, Li L, Fu Y, Sun J. MiR-183 inhibits osteosarcoma cell growth and invasion by regulating LRP6-Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 2018;496(4):1197–1203. doi:10.1016/j.bbrc.2018.01.17029402412
  • Golbakhsh MR, Boddouhi B, Hatami N, et al. Down-regulation of microRNA-182 and microRNA-183 predicts progression of osteosarcoma. Arch Med Sci. 2017;6(6):1352–1356. doi:10.5114/aoms.2016.60091
  • Mu Y, Zhang H, Che L, Li K. Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma. Med Oncol (Northwood, London, England). 2014;31(2):821. doi:10.1007/s12032-013-0821-3
  • Sasaki R, Osaki M, Okada F. MicroRNA-based diagnosis and treatment of metastatic human osteosarcoma. Cancers. 2019;11(4):553. doi:10.3390/cancers11040553
  • Monterde-Cruz L, Ramirez-Salazar EG, Rico-Martinez G, et al. Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population. Hum Cell. 2018;31(4):292–299. doi:10.1007/s13577-018-0214-129907935
  • Yang Z, Wa QD, Lu C, Pan W, Lu Z, Ao J. miR‑328‑3p enhances the radiosensitivity of osteosarcoma and regulates apoptosis and cell viability via H2AX. Oncol Rep. 2018;39(2):545–553. doi:10.3892/or.2017.611229207178
  • Miao F, Zhu J, Chen Y, Tang N, Wang X, Li X. MicroRNA-183-5p promotes the proliferation, invasion and metastasis of human pancreatic adenocarcinoma cells. Oncol Lett. 2016;11(1):134–140. doi:10.3892/ol.2015.387226870180
  • Li J, Fu H, Xu C, et al. miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer. 2010;10:354. doi:10.1186/1471-2407-10-35420602797
  • Zhang L, Quan H, Wang S, Li X, Che X. MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition. Tumour Biol. 2015;36(10):8121–8126. doi:10.1007/s13277-015-3550-825983004
  • Shao JH, Yuan S, Qian QR, Zhu J. MicroRNA-183-5p suppresses the malignant progression of osteosarcoma via binding to AKT. Eur Rev Med Pharmacol Sci. 2019;23(19):8203–8210. doi:10.26355/eurrev_201910_1912731646550